Table 5 Patient demographics of the External Validation Group for Predicted Ultrasomics Phenogroups. Class labels were generated for the external hold out dataset (i.e., the prospective, multicenter, randomized DTU-STEMI pilot trial dataset). Labels were applied based solely on ultrasomics features from the A4C, A3C, and A2C echocardiogram views. Data are considered statistically significant if P ≤ 0.05, denoted by * and bolded text. BMI = body mass index, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, CAD = coronary artery disease, CKD = chronic kidney disease, MACE = major adverse cardiac events, LV = left ventricular

Age (years)

56.82 (48.07–65.57)

58.26 (53.72–62.8)

62.88 (54.99–70.76)

0.48

Sex (Male)

9 (81.82%)

18 (78.26%)

5 (62.5%)

0.60

Race/Ethnicity

Caucasian

Asian American

Hispanic American

Black/African American

8 (72.73%)

1 (9.09%)

0 (0%)

1 (9.09%)

17 (73.91%)

3 (13.04%)

1 (4.55%)

3 (13.04%)

6 (75.00%)

0 (0%)

0 (0%)

2 (25.00%)

0.99

0.58

0.66

0.62

BMI (kg/m²)

30.08 (25.73–34.42)

31.61 (27.35–35.88)

25.61 (21.55–29.67)

0.23

Systolic Blood Pressure (mmHg)

148 (129–167)

158 (143–173)

144 (132–157)

0.44

Diastolic Blood Pressure (mmHg)

93 (81–104)

91 (84–99)

87 (75–99)

0.71

Heart Rate (per minute)

85 (77–93)

91 (81–101)

81 (66–96)

0.45

Left Ventricular Ejection Fraction (%)

36 [27–45]

37 [31–43]

44 [37–51]

0.41

Mitral Valve E Wave (cm/s)

74 (58–91)

77 (69-0.85)

74 (60–89)

0.93

Mitral Valve A Wave (cm/s)

72 (62–83)

69 (59–78)

74 (64–85)

0.71

E/A Ratio

1.07 (0.78–1.37)

1.20 (0.98–1.42)

1.02 (0.79–1.24)

0.55

History of COPD

0 (0%)

0 (0%)

0 (0%)

0.99

History of CAD

1 (9.09%)

1 (4.35%)

1 (12.50%)

0.73

History of CKD

0 (0%)

0 (0%)

0 (0%)

-

History of Diabetes Mellitus

3 (27.27%)

4 (17.39%)

0 (0%)

0.30

History of Hyperlipidemia

7 (63.64%)

9 (39.13%)

4 (50.00%)

0.42

Prior Stroke

1 (9.09%)

0 (0%)

0 (0%)

0.25

MACE − 30 Days

0 (0%)

2 (8.70%)

0 (0%)

0.44

Cardiovascular Death − 30 Days

0 (0%)

0 (0%)

0 (0%)

-

All Cause Mortality − 30 Days

0 (0%)

0 (0%)

0 (0%)

-

Infarct Size (%) of Area at Risk − 5 Days

60 (52–68)**

46 (37–56)

37 (18–56)

0.06

Acute Volume of Infarct Size (mL) − 5 Days

43 [32–54]

31 [20–42]

21 (-4.12-46)

0.17

Acute Infarct Size (%) of LV Mass − 5 Days

23 [17–29]

17 [11–23]

12 (-0.53-25)

0.24

Acute Infarct Size > 10% of LV Mass − 5 Days

9 (82.00%)

14 (61%)

3 (38.00%)

0.07

Acute Volume of Infarct Size (mL) − 30 Days

28 [21–36]

23 [14–32]

14 (-3.10-31)

0.25

Acute Infarct Size (%) of LV Mass − 30 Days

18 [13–22]

14 (8.73-19)

9.23 (-1.31-20)

0.27

Acute Infarct Size > 10% of LV Mass − 30 Days

10 (91.00%)

11 (48.00%)

2 (25.00%)

*<0.01